Advertisement

Topics

Extended-spectrum beta-lactamase-producing Enterobacteriaceae among geckos (Hemidactylus brookii) in a Ghanaian hospital.

08:00 EDT 12th April 2019 | BioPortfolio

Summary of "Extended-spectrum beta-lactamase-producing Enterobacteriaceae among geckos (Hemidactylus brookii) in a Ghanaian hospital."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Pages:

Links

DeepDyve research library

PubMed Articles [7551 Associated PubMed Articles listed on BioPortfolio]

Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients.

Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are a frequent cause of invasive infections worldwide. Carbapenems are nowadays the most used drugs to treat these infections. Howe...

Association between excreta management and extended-spectrum β-lactamase producing Enterobacteriaceae incidence rate: Role of health-care worker's knowledge and practices.

The spread of extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-PE) in healthcare environments has become a major public health threat in recent years.

Carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and the risk of surgical site infection after colorectal surgery: a prospective cohort study.

Antibiotic prophylaxis covering enteric pathogens is essential in preventing surgical site infection (SSI) after colorectal surgery. Current prophylaxis regimens do not cover extended-spectrum beta la...

Risk Factors for Community-Onset Bloodstream Infection with Extended-Spectrum ß-Lactamase-Producing Enterobacteriaceae: National Population-Based Case-Control Study.

To investigate risk factors for community-onset bloodstream infections with extended-spectrum ß-lactamase-producing Enterobacteriaceae (EPE BSI).

The Clinical and Molecular Epidemiology of CTX-M-9 Group Producing Enterobacteriaceae Infections in Children.

The pandemic of extended-spectrum beta-lactamase-(ESBL)-producing Enterobacteriaceae (Ent) is strongly linked to the dissemination of CTX-M-type-ESBL-Ent. We sought to define the epidemiology of infec...

Clinical Trials [3632 Associated Clinical Trials listed on BioPortfolio]

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting results...

Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae

The purposes of this study are: 1. To estimate the prevalence of extended spectrum β-lactamase (ESBL) and/or AmpC among Enterobacteriaceae which cause community-onset urinary trac...

Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

This research will be conducted to determine whether risk factors exist for piperacillin/tazobactam resistance in ESBL organisms.

Optimization Management Study of Community Urinary Tract Infections Spectrum

Urinary tract infections are the second most common community-acquired infections. Even if extended spectrum β-lactamase-producing Enterobacteriaceae (ESBLE) cause fewer urinary tract inf...

Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections

TEMO-CARB is a phase 3, randomized, controlled, multicentre, open-label pragmatic clinical trial to test the non-inferiority of temocillin versus carbapenem as initial intravenous treatmen...

Medical and Biotech [MESH] Definitions

Strains of Enterobacteriaceae that are resistant to CARBAPENEMS, primarily due to the acquisition of carbapenemase (BETA-LACTAMASE) genes.

Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.

A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.

Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It has been proposed especially against Pseudomonas infections.

Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article